EA201070282A1 - Конъюгаты белок-полимер - Google Patents

Конъюгаты белок-полимер

Info

Publication number
EA201070282A1
EA201070282A1 EA201070282A EA201070282A EA201070282A1 EA 201070282 A1 EA201070282 A1 EA 201070282A1 EA 201070282 A EA201070282 A EA 201070282A EA 201070282 A EA201070282 A EA 201070282A EA 201070282 A1 EA201070282 A1 EA 201070282A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein conjugates
polymer protein
polymer
hepatitis
protein
Prior art date
Application number
EA201070282A
Other languages
English (en)
Other versions
EA018111B1 (ru
Inventor
Ко-Чун Линь
Original Assignee
Фармаиссэншиа Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070282(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармаиссэншиа Корп. filed Critical Фармаиссэншиа Корп.
Publication of EA201070282A1 publication Critical patent/EA201070282A1/ru
Publication of EA018111B1 publication Critical patent/EA018111B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение относится к конъюгатам белок-полимер, раскрытым в описании. Кроме того, описан способ получения конъюгата белок-полимер и его применение для лечения инфекции вируса гепатита С или вируса гепатита В.
EA201070282A 2007-08-16 2008-08-15 Конъюгаты белок-полимер и способ лечения инфекции вируса гепатита c или гепатита b EA018111B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95627307P 2007-08-16 2007-08-16
PCT/US2008/073290 WO2009023826A1 (en) 2007-08-16 2008-08-15 Protein-polymer conjugates

Publications (2)

Publication Number Publication Date
EA201070282A1 true EA201070282A1 (ru) 2010-08-30
EA018111B1 EA018111B1 (ru) 2013-05-30

Family

ID=40351178

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070282A EA018111B1 (ru) 2007-08-16 2008-08-15 Конъюгаты белок-полимер и способ лечения инфекции вируса гепатита c или гепатита b

Country Status (30)

Country Link
US (1) US8143214B2 (ru)
EP (2) EP4129343A1 (ru)
JP (1) JP5613050B2 (ru)
KR (1) KR101588465B1 (ru)
CN (1) CN101367872B (ru)
AR (1) AR067964A1 (ru)
AU (1) AU2008286742B2 (ru)
BR (1) BRPI0814482B8 (ru)
CA (1) CA2696478C (ru)
CL (1) CL2008002399A1 (ru)
CY (1) CY1125751T1 (ru)
DK (1) DK2205281T3 (ru)
EA (1) EA018111B1 (ru)
ES (1) ES2924727T3 (ru)
FR (1) FR22C1045I2 (ru)
HR (1) HRP20220937T3 (ru)
HU (2) HUE059551T2 (ru)
LT (1) LT2205281T (ru)
MX (1) MX2010001750A (ru)
MY (1) MY149148A (ru)
NL (1) NL301195I2 (ru)
NO (1) NO2022038I1 (ru)
NZ (1) NZ583831A (ru)
PL (1) PL2205281T3 (ru)
PT (1) PT2205281T (ru)
SI (1) SI2205281T1 (ru)
TW (1) TWI381851B (ru)
UA (1) UA103158C2 (ru)
WO (1) WO2009023826A1 (ru)
ZA (1) ZA201001777B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072850A1 (es) * 2008-07-31 2010-09-22 Pharmaessentia Corp Conjugados peptido-polimero
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
MX2017005244A (es) 2014-11-06 2017-08-18 Pharmaessentia Corp Regimen de dosificacion para interferon pegilado.
CN112433048A (zh) * 2020-11-17 2021-03-02 深圳上泰生物工程有限公司 一种用于化学发光免疫法的试剂盒及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
MXPA02001969A (es) * 1999-08-27 2003-07-21 Maxygen Aps Nuevas moleculas similares a interferon beta.
CA2390292A1 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
KR20070072924A (ko) * 2001-11-20 2007-07-06 파마시아 코포레이션 화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
HUE028163T2 (en) * 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
US7345150B2 (en) 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
KR100974843B1 (ko) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
CA2510040C (en) * 2003-05-23 2012-01-03 Nektar Therapeutics Al, Corporation Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages
US7405198B2 (en) * 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
AP2007003919A0 (en) 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1869079A2 (en) * 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CN101636414B (zh) 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2b及其制备方法和应用
PT2196475E (pt) 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
DK2205281T3 (da) 2022-08-15
FR22C1045I2 (fr) 2023-12-29
AU2008286742A1 (en) 2009-02-19
CY1125751T1 (el) 2023-06-09
NL301195I1 (ru) 2022-08-31
HUE059551T2 (hu) 2022-11-28
WO2009023826A1 (en) 2009-02-19
NZ583831A (en) 2012-06-29
MY149148A (en) 2013-07-15
TWI381851B (zh) 2013-01-11
EP2205281B1 (en) 2022-06-29
CN101367872A (zh) 2009-02-18
EA018111B1 (ru) 2013-05-30
AR067964A1 (es) 2009-10-28
US20090053177A1 (en) 2009-02-26
LT2205281T (lt) 2022-09-26
MX2010001750A (es) 2010-06-01
NL301195I2 (nl) 2023-03-02
SI2205281T1 (sl) 2022-11-30
US8143214B2 (en) 2012-03-27
NO2022038I1 (no) 2022-09-02
ES2924727T3 (es) 2022-10-10
HRP20220937T3 (hr) 2022-09-30
TW200916116A (en) 2009-04-16
FR22C1045I1 (fr) 2022-10-14
KR20100076945A (ko) 2010-07-06
EP2205281A1 (en) 2010-07-14
BRPI0814482B8 (pt) 2021-11-23
CN101367872B (zh) 2013-11-20
ZA201001777B (en) 2010-12-29
HUS2200039I1 (hu) 2022-09-28
EP4129343A1 (en) 2023-02-08
JP2010536788A (ja) 2010-12-02
AU2008286742B2 (en) 2014-05-29
CA2696478A1 (en) 2009-02-19
CA2696478C (en) 2018-10-09
JP5613050B2 (ja) 2014-10-22
CL2008002399A1 (es) 2009-01-02
EP2205281A4 (en) 2014-10-08
BRPI0814482B1 (pt) 2021-02-02
PL2205281T3 (pl) 2022-12-12
UA103158C2 (ru) 2013-09-25
KR101588465B1 (ko) 2016-01-25
PT2205281T (pt) 2022-08-02
BRPI0814482A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
CY1119988T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA200700243A1 (ru) Способы лечения гепатита с
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
EA200901241A1 (ru) Соединения для лечения гепатита с
WO2010047830A3 (en) Agents for hcv treatment
EA201390538A1 (ru) Противовирусные соединения
EA201100390A1 (ru) Соединения для лечения гепатита с
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
EA201490588A1 (ru) Способы лечения вируса гепатита с
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
EA201170353A1 (ru) Антитела против гепатита с и их применение
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
NO20090453L (no) Hepatitt C Virusinhibitorer
EA201101082A1 (ru) Ингибиторы вируса гепатита с
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
CY1125751T1 (el) Συμπλοκα πρωτεϊνων-πολυμερων
EA201000277A1 (ru) Соединения для лечения гепатита с
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950